ASD Closure Surgery in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Children and adults diagnosed with hemodynamically significant Ostium Secundum ASD with a Qp:Qs ratio ≥ 1.5:1 confirmed on echocardiography or cardiac MRI

• Patients with right ventricular volume overload, right heart dilation, or exercise intolerance attributable to the ASD

• Adults presenting with cryptogenic stroke or TIA in whom paradoxical embolism through a patent ASD or large PFO is suspected

• Patients with Ostium Secundum defects ≤ 38 mm diameter with adequate septal rim tissue (≥ 5 mm on all rims except the aortic rim) for transcatheter device closure

• Patients with anatomically complex defects (sinus venosus, primum, multiple fenestrated defects, deficient posterior/inferior rim) who require surgical repair

• Symptomatic patients with atrial arrhythmias (atrial fibrillation or flutter) secondary to right atrial enlargement from ASD

• REQUIRED DIAGNOSTIC WORKUP:

• Transthoracic Echocardiogram (TTE): First-line imaging to identify defect, estimate shunt size, and assess right heart dimensions

• Transesophageal Echocardiogram (TEE) or 3D TEE: Mandatory for precise defect sizing, rim assessment, and intraprocedural guidance during transcatheter closure

• Cardiac MRI (CMR): Gold standard for accurate Qp:Qs quantification and right ventricular volumetry when echocardiographic windows are suboptimal

• Chest X-Ray: Assesses cardiomegaly, pulmonary plethora, and mediastinal widening

• 12-Lead ECG: May reveal right bundle branch block (rSR' pattern in V1), right axis deviation, or atrial arrhythmias

• Cardiac Catheterization (Right Heart Cath): Required when pulmonary hypertension is suspected — measures PCWP, PAP, and calculates PVR in Wood units; vasoreactivity testing with nitric oxide may be performed

• CT Pulmonary Angiography or Cardiac CT: Useful for sinus venosus defects and anomalous pulmonary venous connections

• Complete Blood Count, Coagulation Profile (PT/INR/aPTT), Renal and Hepatic Function Tests, Blood Group and Crossmatch

• Pediatric patients: Developmental assessment, weight-for-age charts (minimum weight threshold of ~8 kg typically required for transcatheter approach)

• CONTRAINDICATIONS:

• Severe irreversible pulmonary arterial hypertension (PVR > 8 Wood units unresponsive to vasodilator testing — Eisenmenger physiology): Closure is contraindicated as it may precipitate fatal right heart failure

• Net right-to-left shunting (reversed shunt): Closure is absolutely contraindicated

• Active systemic infection or sepsis

• Intracardiac thrombus

• Anatomical unsuitability for device closure without sufficient surgical backup

• Severe coagulopathy uncorrectable before procedure

• Allergy to nickel/titanium (relative contraindication for nitinol-based occluder devices — skin patch testing recommended preoperatively)

ASD closure is not a single procedure — the optimal approach is individualized based on defect anatomy, patient age, body size, pulmonary hemodynamics, and the presence of associated cardiac anomalies. The following techniques represent the current spectrum of care:

1. TRANSCATHETER DEVICE CLOSURE (Preferred for Eligible Secundum ASDs) This is the first-line treatment for Ostium Secundum ASDs with adequate rim tissue and a stretched diameter ≤ 38 mm. Performed under general anesthesia or deep sedation in a hybrid catheterization laboratory, a venous sheath is advanced from the femoral vein through the inferior vena cava and across the ASD into the left atrium. A sizing balloon catheter is used to measure the stretched diameter of the defect. A self-expanding nitinol double-disc occluder — most commonly the Amplatzer Septal Occluder (ASO) or GORE CARDIOFORM device — is deployed under real-time 2D/3D transesophageal echocardiography (TEE) and fluoroscopic guidance. The device is repositioned and recaptured until optimal positioning is confirmed, then released. Complete defect closure is assessed immediately by color Doppler. The procedure typically takes 45–90 minutes. Patients are anticoagulated with unfractionated heparin intraprocedurally and maintained on aspirin (75–100 mg/day) for 6 months post-procedure, with some protocols adding clopidogrel for 3 months (dual antiplatelet therapy) during device endothelialization. Intracardiac Echocardiography (ICE) is an emerging alternative to TEE that allows the procedure to be performed under conscious sedation without general anesthesia, and is available in several advanced centers in India and the UAE.

2. MINIMALLY INVASIVE SURGICAL CLOSURE — RIGHT MINI-THORACOTOMY For patients who are not candidates for transcatheter closure (large defects, deficient rims, sinus venosus ASD with anomalous pulmonary veins, primum ASD, or failed device closure), surgical repair via a right anterolateral mini-thoracotomy (3–5 cm incision) offers excellent results with minimal scarring. Cardiopulmonary bypass is established via femoral or peripheral cannulation. The ASD is closed either by direct suture repair (for small defects) or with an autologous pericardial or synthetic (Gore-Tex/Dacron) patch for larger defects. Concurrent repair of partial anomalous pulmonary venous return (PAPVR) is performed when present. This approach avoids median sternotomy, reducing blood loss, ICU stay, and recovery time significantly compared to conventional surgery.

3. PORT-ACCESS AND ROBOTIC-ASSISTED CARDIAC SURGERY Select high-volume centers in India (Chennai, Hyderabad) and the UAE (Abu Dhabi, Dubai) offer port-access or fully robotic ASD closure using the da Vinci Surgical System. The robotic platform provides 3D magnification and articulated instrumentation through 8–12 mm ports, enabling precise suturing on the arrested heart through the lateral chest wall. This technique is particularly favored for adult patients with secundum ASDs unsuitable for transcatheter closure, offering exceptional cosmetic outcomes, minimal blood loss, shorter ICU stay (12–24 hours), and return to full activity within 3–4 weeks. It requires advanced robotic cardiac surgery expertise and appropriate patient selection (BMI, prior thoracic surgery, cardiac anatomy).

4. CONVENTIONAL OPEN SURGICAL REPAIR — MEDIAN STERNOTOMY Still the standard for complex congenital lesions — Ostium Primum ASD (which involves cleft mitral valve repair), complete atrioventricular septal defects (AVSD), sinus venosus defects with complex anomalous venous drainage, and redo cardiac surgery. Cardiopulmonary bypass with cardioplegic arrest, direct visualization, and patch repair are performed. Operative mortality in experienced centers for isolated ASD closure via sternotomy is less than 0.5%.

5. HYBRID AND PERVENTRICULAR APPROACHES For very small patients (weight < 8 kg) in whom standard femoral transcatheter access is technically challenging, a perventricular (intraoperative, off-pump, direct right ventricular puncture) approach to device delivery is used at specialized pediatric cardiac centers, avoiding full cardiopulmonary bypass while still achieving device closure under TEE guidance.

PHASE 1 — PRE-ARRIVAL & CONSULTATION (Weeks 1–2 before travel)

• GAF Healthcare coordinates a virtual second-opinion consultation between the patient/family and the treating pediatric cardiologist or cardiac surgeon at the chosen center

• All prior records (echocardiography reports, cardiac MRI, catheterization data, ECGs, blood work) are reviewed digitally

• The clinical team confirms the closure strategy (transcatheter vs. surgical) and schedules the procedure date

• GAF Healthcare initiates e-Medical Visa application for India (typically approved within 3–5 business days) or visa-on-arrival/prior visa arrangements for UAE

• Pre-procedure blood tests, infectious disease screening (HIV, HBsAg, HCV, MRSA nasal swab), and anesthesia pre-assessment forms are completed remotely where possible

PHASE 2 — ARRIVAL & PRE-OPERATIVE ASSESSMENT (Day 1–2)

• GAF Healthcare's ground team receives patient and family at the airport with a dedicated vehicle

• Admission to hospital; repeat TTE/TEE performed by the treating team to re-assess defect anatomy on-site

• Anesthesiology and cardiac surgery/interventional cardiology teams conduct in-person pre-operative assessment

• Pediatric patients undergo weight-based drug dosing calculations; NPO (nil-by-mouth) protocol initiated night before procedure

• Consent process: detailed informed consent obtained covering procedure specifics, device type (for transcatheter), risks, and contingency plans (e.g., conversion to surgical closure if device deployment is unsatisfactory)

• Pre-operative anticoagulation or antiplatelet protocol initiated as per center protocol

PHASE 3 — THE PROCEDURE (Day 2 or 3)

• TRANSCATHETER CLOSURE: Patient taken to hybrid cath lab under general anesthesia or deep sedation. TEE probe placed. Femoral venous access obtained. Balloon sizing performed. Device selected and deployed. Procedural duration: 60–90 minutes. Patient recovers in post-anesthesia care unit (PACU) for 2–4 hours, then transferred to pediatric cardiac ward.

• SURGICAL CLOSURE (Mini-thoracotomy or Open): Patient brought to cardiac operating room. General anesthesia induced. Cardiopulmonary bypass established. Cardiac arrest achieved with cold blood cardioplegia. ASD repaired under direct vision (suture or patch). Bypass discontinued. Chest closed. Procedural duration: 2.5–4 hours. Patient transferred to pediatric cardiac ICU (PCICU).

PHASE 4 — IMMEDIATE POST-OPERATIVE RECOVERY (Days 3–7)

• TRANSCATHETER patients: Monitored overnight on the cardiac ward. Chest X-ray and TTE performed on post-procedure Day 1 to confirm device position and exclude pericardial effusion. Discharged on Day 2–3 post-procedure on aspirin ± clopidogrel. Activity restrictions: avoid strenuous activity for 2–4 weeks; no contact sports for 6 months (during device endothelialization period).

• SURGICAL patients: Typically 12–24 hours in PCICU. Chest drain(s) removed by Day 2. Epidural or IV analgesia transitioned to oral. Mobilization begins Day 1–2 post-op. Respiratory physiotherapy and incentive spirometry initiated. Discharged from hospital by Day 5–7 if recovery is uneventful. Wound care instructions provided.

• All patients: Subacute bacterial endocarditis (SBE) prophylaxis recommended for 6 months post-device placement (transcatheter) or per surgical team guidance.

PHASE 5 — IN-COUNTRY RECOVERY BEFORE FLIGHT (Weeks 1–4 post-procedure)

• Transcatheter closure patients: A 2-week in-country stay post-procedure is standard before international air travel clearance. Follow-up TTE at Day 7–10 confirms stable device position and absence of residual shunt or pericardial effusion. Flight clearance is given by the treating cardiologist based on clinical and echocardiographic assessment.

• Surgical closure patients: A minimum 3–4 week in-country stay is required. Sternal/thoracotomy wound healing, normalization of inflammatory markers, and stable cardiac function on echo are prerequisites for fit-to-fly clearance. Patients should not travel in pressurized cabins until their cardiologist confirms absence of pleural effusion or pneumothorax on chest X-ray.

• GAF Healthcare arranges serviced apartment or hotel accommodation with medical-grade support for the recovery period, with a dedicated case manager available 24/7.

PHASE 6 — LONG-TERM FOLLOW-UP (Post-return)

• Follow-up echocardiogram at 1 month, 6 months, and 12 months post-procedure (can be coordinated with a local cardiologist in the patient's home country, with reports shared with the treating team)

• Antiplatelet therapy (aspirin) continued for 6 months post-transcatheter device placement, then discontinued if no residual shunt on echo

• Annual cardiology review for at least 3–5 years to monitor for late complications: device erosion (rare, ~0.1%), atrial arrhythmias, residual shunt, thrombus on device

• Patients who had pulmonary hypertension pre-closure require serial right heart assessments to confirm normalization of pulmonary arterial pressure